focus -WSS

focus

author：knowledge 2025-10-01 02:16:13 - browse：83937

A doctor climbs up a red ladder to a vine shaped like a DNA — biotech coverage from STAT — Adobe

Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the hall, and helps her 8-year-old daughter Addi slide into a set of contraptions that squeeze and suck out the thick mucus constantly threatening to choke her airways closed. She feeds Addi breakfast through a stomach tube and makes sure she has the right mix of the 28 different medications required to keep her free of pain, infections, and seizures. At some point, Rasberry’s five other children will wake up and start to get ready for school, including her youngest, Oliver. At 3-and-a-half years old, he’s a typical toddler — always running and giggling and getting into things. You would never know that he and Addi were born with the same mutation lurking in their DNA, a genetic glitch that causes a fatal neurodegenerative disease called metachromatic leukodystrophy, or MLD.

“When Addi was this age she had lost the ability to speak and was already using a ventilator to sleep at night,” Rasberry said. “It’s amazing to see how well Ollie is doing in comparison. And it’s all because of the gene therapy.”

Three years ago, when Ollie was just 6 months old, he and Victoria traveled from their home in Texas to Milan, to receive a gene therapy treatment that adds a healthy version of the defective gene into patients’ own stem cells. At the time, traveling abroad for the therapy, which is manufactured by Orchard Therapeutics and was approved in Europe in 2021, was the only option for families stricken by MLD. But soon it will be available in the U.S., too.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Grail is spending more than ever lobbying Congress

WSS

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Van's Gluten Free Original Waffles recalled for possible wheat allergen

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Weight bias in eating disorder treatment complicated by new weight loss drugs

Why we need to separate burnout from moral injury in health care

Pfizer's Covid pill remains 89% effective in final analysis, company says

hotspot

focus

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

State Dept. review finds Biden bears some blame for Afghanistan failures

Colonoscopy at 40? Study finds a possible benefit

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

#NeedHerScience: shining a light on gender disparities in medicine

Wildfire smoke exposes gaps in outdoor worker protections

#NeedHerScience: shining a light on gender disparities in medicine

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

entertainment

Gene therapy has helped boys walk. Can scientists keep it that way?

The story of mRNA: From a loose idea to a tool that may help curb Covid

Connecting traumatic brain injury and domestic violence

With FDA staff opposed to Sarepta therapy, top official intervened

Paxlovid study fails to answer questions over benefit for broader groups

Colonoscopy at 40? Study finds a possible benefit

knowledge

hotspot

entertainment

focus